Benign Prostatic Hyperplasia Treatment Market Size, Trend Analysis & Competition Tracking By Drug Classes (Alpha Blockers, 5-Alpha-reductase Inhibitors (5-ARIs), Phosphodiesterase-5 Enzyme Inhibitors), By Minimally-invasive Surgeries, By Laser Therapy - Global Market Insights to 2027

Educational Campaigns Augmenting Patient Base for Benign Prostatic Hyperplasia Treatment

There has been alarming rise in the number of patients suffering from benign prostatic hyperplasia (BPH), demanding central authorities to take strong action and control the progression

progression of this condition. According to a study published by the Canadian Journal of Urology, around 50% men are likely to suffer from BPH by the age of 50 years. This has led to an increase in awareness campaigns by central healthcare bodies.

For instance, every year, September is observed as the 'National Prostate Health Month' in North America, aimed at educating men regarding the risks pertaining to BPH conditions, which is increasing the patient base for availing diagnosis and proper treatment. On the back of the steady rise in demand for therapeutics, a recent study by Fact.MR portends that, the benign prostatic hyperplasia treatment market would record a value tantamount to US$ 12 Bn by 2027.

Loss of Patent Exclusivity Creating Lucrative Ground for Generic Drugs

Instances of patent expirations have been long-influencing the revenue of the benign prostatic hyperplasia treatment market. As per the study, 2024 will witness patent expiration of key BPH treatment drugs, such as Avodart, Cialis, Jalyn, and Rapaflo. Absence of branded drugs opens lucrative avenues for regional and local players to increase investments towards the development of generic drugs and biosimilar products.

Low-cost impact of generic drugs limits the sales opportunities for branded drugs, which creates concerns for leading players, as they invest huge capital to fuel their R&D activities. Though the sales of generic drugs fillip the growth of the BPH treatment market, their revenue contribution is significantly lesser as compared to branded drugs.

Market Share of Minimally-invasive Surgeries to Grow, while Drug Class Retains Pole Position

Nearly 50% of the total revenue in the benign prostatic hyperplasia treatment market is projected to arrive from drug classes by 2027. Availability of short-term and long-term alpha inhibitors that lower blood pressure and improve blood flow is found to relieve symptoms of BPH, which has led and continues to lead to the high adoption of these drugs.

However, introduction of surgeries and therapeutics that relieve symptoms in one go in tandem with rising awareness regarding the side-effects of drugs, such as dizziness and nausea, is likely to move the market share accounted by minimally-invasive surgeries to a higher value.

Rise in Medical Tourism Catapulting Indian Benign Prostatic Hyperplasia Treatment Market

According to the Fact.MR study, the typical cost of transurethral resection of the prostate (TURP) in the U.S. ranges from US$ 8,000 to US$ 12,000, while cost of the same surgery in India is significantly lower (around US$ 1,500 to US$ 6,000). Cost benefits of TURP surgery in India are despite the use of cutting-edge technology and diagnostic equipment by surgeons for offering better patient outcomes.

This is creating a novel revenue stream for the benign prostatic hyperplasia treatment market through medical tourism, especially driven from patients from Western countries such as the U.S. and the U.K. Also, hospitals—both, private and public—are free from long waitlists, and India has also relaxed visa policies, which further turns the country favourable for medical tourism.

A similar trend is being witnessed in the BPH treatment market in Japan. High technological advancements are complementing developmental efforts of manufacturers, such as Olympus Corporation, Astellas Pharma, Inc., Asahi Kasei Corporation, operating in Japan. On the back of medical tourism strengthening demand and intense R&D efforts ensuring long-term supply, the benign prostatic hyperplasia treatment market in Asia Pacific is witnessing an accelerated pace, projected to expand at a CAGR of 7.3% during the forecast period.

Benign Prostatic Hyperplasia Market – Assessment of Key Segments

Authors of this comprehensive study have classified the BPH treatment market into key segments for an in-depth study of the market. Categorisation of the benign prostatic hyperplasia treatment market is based on treatment type, end user, and region. This detailed study also offers information about the incremental opportunities present in the benign prostatic hyperplasia treatment market during the forecast period. Key segments considered while studying the benign prostatic hyperplasia treatment market include:

Revenue of the benign prostatic hyperplasia treatment market has been estimated in terms of US$ Mn for the period of 2020 to 2027. In addition to this, compound annual growth rate (CAGR %) has been estimated for all segments during the forecast period 2020-2027, considering 2019 as the base year, in the benign prostatic hyperplasia treatment market.

Research analysts of the study on the benign prostatic hyperplasia treatment market have focused on leading, prominent, and emerging players, which include Olympus Corporation, Boston Scientific Corporation, LISA Laser, Teleflex Incorporated, Urologix, LLC, and Endo International PLC.